Status:
UNKNOWN
Expiratory and Plasma Propofol Concentration in Gastrological Surgery Patients
Lead Sponsor:
Oslo University Hospital
Conditions:
Bariatric Surgery Candidate
Cholecystectomy
Eligibility:
All Genders
18-60 years
Phase:
NA
Brief Summary
Determination of accuracy With Edmond (reg) expiratory propofol measurement Device, compared With concommitant plasma samples of propofol
Detailed Description
Edmon (trade mark) is a New Device from BBraun, measuring the expiratory concentration of propofol in anaesthetized patients. The investigators will test the accuracy and stability of such measuremen...
Eligibility Criteria
Inclusion
- • Patients admitted to Oslo University Hospital, scheduled for elective laparoscopic bariatric surgery or elective laparoscopic cholecystectomy.
- Both genders.
- Age 18-60 years, both inclusive.
- BMI ≥ 20 kg/m2, 10 patients with BMI 20-30, and 10 patients with BMI \> 40
- ASA classification I-III
Exclusion
- • Known hypersensitivity or other contraindication to propofol administered as Target Controlled Infusion.
- Patients which during a preoperative visit are deemed not to tolerate propofol bolus or infusion as administered by Target Controlled Infusion.
- Ongoing neuroleptic medication.
Key Trial Info
Start Date :
November 14 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2020
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT03817541
Start Date
November 14 2018
End Date
December 31 2020
Last Update
February 5 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dept of Anesthesiology, Oslo University Hospital, Ullevaal
Oslo, Norway, 0407